1. bookVolume 15 (2022): Edizione 1 (June 2022)
Dettagli della rivista
License
Formato
Rivista
eISSN
1313-9053
Prima pubblicazione
08 Sep 2014
Frequenza di pubblicazione
2 volte all'anno
Lingue
Inglese
Accesso libero

A Retrospective Analysis of Treatment of Covid-19 with Favipiravir

Pubblicato online: 13 Jul 2022
Volume & Edizione: Volume 15 (2022) - Edizione 1 (June 2022)
Pagine: 74 - 78
Ricevuto: 22 Jul 2021
Accettato: 11 May 2022
Dettagli della rivista
License
Formato
Rivista
eISSN
1313-9053
Prima pubblicazione
08 Sep 2014
Frequenza di pubblicazione
2 volte all'anno
Lingue
Inglese

1. Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. 2020;83(6):534-6.10.1097/JCMA.0000000000000318717626632243270 Search in Google Scholar

2. World Health Organization. Weekly epidemiological update on COVID-19 - 13 July 2021 [cited July 15, 2021]. In: World Health Organization [Internet]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021 Search in Google Scholar

3. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am. J. Emerg. Med. 2020;38(7):1488-93. Search in Google Scholar

4. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 2013;100(2):446-54. Search in Google Scholar

5. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil. Med. Res. 2020;7(1):11. Search in Google Scholar

6. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;6(10), 1192-8. Search in Google Scholar

7. Çalık Başaran N, Uyaroğlu OA, Telli Dizman G, Özışık L, Şahin TK, Taş Z, et al. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turk. J. Med. Sci. 2021;51(2):411-20. Search in Google Scholar

8. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020. DOI: https://doi.org/10.1101/2020.03.17.20037432 Search in Google Scholar

9. Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. Eur. J. Pharm. Sci. 2021;157.10.1016/j.ejps.2020.105631758571933115675 Search in Google Scholar

10. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN., еt al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;ciaa1176.10.1093/cid/ciaa1176745438832770240 Search in Google Scholar

11. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. (2020). Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virology Journal. 2020;17(1):141. Search in Google Scholar

12. [Clinical protocol for the diagnosis and treatment of coronavirus infection COVID-19]. Protocol No. 107, Approved by the Joint Commission on the Quality of Medical Services of the Ministry of Health of the Republic of Kazakhstan dated July 15, 2020. Available from: www.gov.kz Russian. Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo